Alcista
$1.83
Precio del escenario
$5.810
+0.071 (+1.22%)Al cierre
Lifeward Ltd, formerly known as ReWalk Robotics Ltd, is a medical device company. The Company is engaged in designing, developing, and commercializing exoskeletons that allow individuals with mobility impairments or other medical conditions the ability to stand and walk again. The Company offers an exoskeleton that uses its tilt-sensor technology and an onboard computer and motion sensors to drive motorized legs that power movement. Lifeward designs are intended for people with paraplegia, a spinal cord injury resulting in complete or incomplete paralysis of the legs, having the use of their upper bodies and arms. The Company offers multiple products: ReWalk Personal, ReStore Exo-Suit, MYOLYN FES Cycling, and AlterG Anti-Gravity Systems. ReWalk Personal is designed for everyday use by paraplegic individuals at home and in their communities and is custom-fitted for each user. Lifeward Rehabilitation products are for use by paraplegia patients in the clinical rehabilitation environment.
ReWalk Robotics Ltd (LFWD) is not a good buy right now due to its current price of $5.81 being significantly below its 52-week high of $9.61, and the RSI at 45.1 suggests it is neither overbought nor oversold, indicating a lack of strong momentum. Additionally, the company reported a net income loss of $11.5 million in Q2 2026, which raises concerns about its profitability.
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.

Lifeward Releases Updated Investor Presentation Highlighting Strategic Growth

Lifeward Reports 16% Revenue Growth in Q2 2026

Oramed Pharmaceuticals Joins Russell Indexes, Strengthens Financial Position

Lifeward (LFWD) Q4 2025 Earnings Transcript

Lifeward Appoints New Chief Medical Officer
Lifeward Ltd, formerly known as ReWalk Robotics Ltd, is a medical device company. The Company is engaged in designing, developing, and commercializing exoskeletons that allow individuals with mobility impairments or other medical conditions the ability to stand and walk again. The Company offers an exoskeleton that uses its tilt-sensor technology and an onboard computer and motion sensors to drive motorized legs that power movement. Lifeward designs are intended for people with paraplegia, a spinal cord injury resulting in complete or incomplete paralysis of the legs, having the use of their upper bodies and arms. The Company offers multiple products: ReWalk Personal, ReStore Exo-Suit, MYOLYN FES Cycling, and AlterG Anti-Gravity Systems. ReWalk Personal is designed for everyday use by paraplegic individuals at home and in their communities and is custom-fitted for each user. Lifeward Rehabilitation products are for use by paraplegia patients in the clinical rehabilitation environment. It operates in the Healthcare sector (ORTHOPEDIC, PROSTHETIC, AND SURGICAL APPLIANCES AN industry).
ReWalk Robotics Ltd (LFWD) is not a good buy right now due to its current price of $5.81 being significantly below its 52-week high of $9.61, and the RSI at 45.1 suggests it is neither overbought nor oversold, indicating a lack of strong momentum. Additionally, the company reported a net income loss of $11.5 million in Q2 2026, which raises concerns about its profitability.
Aún no hay publicaciones
Regístrate o inicia sesión para participarEsta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.